Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Human 5' UTR design and variant effect prediction from a massively parallel translation assay.

Sample PJ, Wang B, Reid DW, Presnyak V, McFadyen IJ, Morris DR, Seelig G.

Nat Biotechnol. 2019 Jul;37(7):803-809. doi: 10.1038/s41587-019-0164-5. Epub 2019 Jul 1.

PMID:
31267113
2.

Oligonucleotide Sequence Mapping of Large Therapeutic mRNAs via Parallel Ribonuclease Digestions and LC-MS/MS.

Jiang T, Yu N, Kim J, Murgo JR, Kissai M, Ravichandran K, Miracco EJ, Presnyak V, Hua S.

Anal Chem. 2019 Jul 2;91(13):8500-8506. doi: 10.1021/acs.analchem.9b01664. Epub 2019 Jun 10.

PMID:
31129964
3.

High density lipoprotein promotes nascent apolipoprotein A-V secretion from mRNA transfected cells.

Romenskaia I, DeAntonis CM, Presnyak V, Schultz JR, Ryan RO.

Biochem Biophys Res Commun. 2019 Apr 30;512(2):387-391. doi: 10.1016/j.bbrc.2019.03.087. Epub 2019 Mar 20.

PMID:
30902391
4.

Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.

Zhu X, Yin L, Theisen M, Zhuo J, Siddiqui S, Levy B, Presnyak V, Frassetto A, Milton J, Salerno T, Benenato KE, Milano J, Lynn A, Sabnis S, Burke K, Besin G, Lukacs CM, Guey LT, Finn PF, Martini PGV.

Am J Hum Genet. 2019 Apr 4;104(4):625-637. doi: 10.1016/j.ajhg.2019.02.003. Epub 2019 Mar 14.

PMID:
30879639
5.

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia.

An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, Theisen M, Hong SJ, Zhou J, Rajendran R, Levy B, Howell R, Besin G, Presnyak V, Sabnis S, Murphy-Benenato KE, Kumarasinghe ES, Salerno T, Mihai C, Lukacs CM, Chandler RJ, Guey LT, Venditti CP, Martini PGV.

Cell Rep. 2018 Aug 28;24(9):2520. doi: 10.1016/j.celrep.2018.08.049. No abstract available.

6.

Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia.

An D, Schneller JL, Frassetto A, Liang S, Zhu X, Park JS, Theisen M, Hong SJ, Zhou J, Rajendran R, Levy B, Howell R, Besin G, Presnyak V, Sabnis S, Murphy-Benenato KE, Kumarasinghe ES, Salerno T, Mihai C, Lukacs CM, Chandler RJ, Guey LT, Venditti CP, Martini PGV.

Cell Rep. 2017 Dec 19;21(12):3548-3558. doi: 10.1016/j.celrep.2017.11.081. Erratum in: Cell Rep. 2018 Aug 28;24(9):2520.

7.

N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density.

Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N.

Nucleic Acids Res. 2017 Jun 2;45(10):6023-6036. doi: 10.1093/nar/gkx135.

8.

Codon optimality is a major determinant of mRNA stability.

Presnyak V, Alhusaini N, Chen YH, Martin S, Morris N, Kline N, Olson S, Weinberg D, Baker KE, Graveley BR, Coller J.

Cell. 2015 Mar 12;160(6):1111-24. doi: 10.1016/j.cell.2015.02.029.

9.

The DHH1/RCKp54 family of helicases: an ancient family of proteins that promote translational silencing.

Presnyak V, Coller J.

Biochim Biophys Acta. 2013 Aug;1829(8):817-23. doi: 10.1016/j.bbagrm.2013.03.006. Epub 2013 Mar 23. Review.

10.

TbRGG2 facilitates kinetoplastid RNA editing initiation and progression past intrinsic pause sites.

Ammerman ML, Presnyak V, Fisk JC, Foda BM, Read LK.

RNA. 2010 Nov;16(11):2239-51. doi: 10.1261/rna.2285510. Epub 2010 Sep 20.

11.

Distinct and overlapping functions of MRP1/2 and RBP16 in mitochondrial RNA metabolism.

Fisk JC, Presnyak V, Ammerman ML, Read LK.

Mol Cell Biol. 2009 Oct;29(19):5214-25. doi: 10.1128/MCB.00520-09. Epub 2009 Jul 20.

12.

A type III protein arginine methyltransferase from the protozoan parasite Trypanosoma brucei.

Fisk JC, Sayegh J, Zurita-Lopez C, Menon S, Presnyak V, Clarke SG, Read LK.

J Biol Chem. 2009 Apr 24;284(17):11590-600. doi: 10.1074/jbc.M807279200. Epub 2009 Mar 2.

13.

TbRGG2, an essential RNA editing accessory factor in two Trypanosoma brucei life cycle stages.

Fisk JC, Ammerman ML, Presnyak V, Read LK.

J Biol Chem. 2008 Aug 22;283(34):23016-25. doi: 10.1074/jbc.M801021200. Epub 2008 Jun 26.

14.

Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding.

Bennett RP, Presnyak V, Wedekind JE, Smith HC.

J Biol Chem. 2008 Mar 21;283(12):7320-7. doi: 10.1074/jbc.M708567200. Epub 2007 Dec 28.

15.

Supplemental Content

Loading ...
Support Center